Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Femasys Inc (FEMY)

Femasys Inc (FEMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,630
  • Shares Outstanding, K 60,391
  • Annual Sales, $ 2,290 K
  • Annual Income, $ -18,630 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta -2.28
  • Price/Sales 11.16
  • Price/Cash Flow N/A
  • Price/Book 4.22
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.50
  • Most Recent Earnings $-0.01 on 03/31/26
  • Next Earnings Date 05/14/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.23
  • Growth Rate Est. (year over year) +434,447.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3305 +26.14%
on 03/30/26
0.5500 -24.20%
on 03/23/26
-0.1405 (-25.21%)
since 03/20/26
3-Month
0.3305 +26.14%
on 03/30/26
0.6587 -36.71%
on 01/22/26
-0.2225 (-34.80%)
since 01/21/26
52-Week
0.3067 +35.93%
on 08/26/25
1.2900 -67.68%
on 04/24/25
-0.7831 (-65.26%)
since 04/21/25

Most Recent Stories

More News
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio

-- Partnership with AMI Technologies Positions FemaSeed ® as a First-Line Infertility Treatment in Israel, Expanding Market Access to Innovative Fertility Solutions --  ATLANTA, April 16, 2026...

FEMY : 0.4169 (-1.77%)
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 0.4169 (-1.77%)
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 0.4169 (-1.77%)
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 0.4169 (-1.77%)
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

-- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10,...

FEMY : 0.4169 (-1.77%)
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access

-- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance -- ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:...

FEMY : 0.4169 (-1.77%)
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical...

FEMY : 0.4169 (-1.77%)
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products

ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to...

FEMY : 0.4169 (-1.77%)
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a leading biomedical innovator making fertility and non-surgical permanent birth control...

FEMY : 0.4169 (-1.77%)
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

ATLANTA , Jan. 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 0.4169 (-1.77%)

Business Summary

Femasys Inc.is a biomedical company focused on transforming women's healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The company's lead product candidates offer FemBloc and FemaSeed. Femasys Inc. is based in ATLANTA.

See More

Key Turning Points

3rd Resistance Point 0.4551
2nd Resistance Point 0.4447
1st Resistance Point 0.4308
Last Price 0.4169
1st Support Level 0.4065
2nd Support Level 0.3961
3rd Support Level 0.3822

See More

52-Week High 1.2900
Fibonacci 61.8% 0.9144
Fibonacci 50% 0.7983
Fibonacci 38.2% 0.6823
Last Price 0.4169
52-Week Low 0.3067

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.